Skip to main content
Erschienen in: Herz 1/2017

18.01.2017 | Kardiogener Schock | Schwerpunkt

Einsatz von Vasopressoren und Inotropika im kardiogenen Schock

verfasst von: H. Lemm, S. Dietz, M. Janusch, Prof. Dr. med. M. Buerke

Erschienen in: Herz | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Vasoaktive Medikamente und Inotropika sind wichtige Bausteine im hämodynamischen Management des kardiogenen Schocks. In diesem Beitrag wird der Einsatz der unterschiedlichen vasoaktiven und ionotropen Medikamente beim kardiogenen Schock dargestellt. Das hämodynamische Management beim kardiogenen Schock erfolgt nach initialer moderater Volumengabe durch Dobutamin zur Steigerung der Inotropie. Wenn keine ausreichenden Perfusionsdrücke erzielt werden, erfolgt die Gabe von Noradrenalin. Sollte weiterhin keine suffiziente Steigerung der Herzleistung erreicht werden, kann die Gabe von Levosimendan oder Phosphodiesterase (PDE)-Hemmern erfolgen. Levosimendan ist bei Patienten im kardiogenem Schock den PDE-Hemmern vorzuziehen. Ziel des hämodynamischen Managements bei kardiogenem Schock ist der passagere Einsatz von Inotropika und Vasopressoren in der geringsten notwendigen Dosis und nur so lange wie notwendig. Es muss täglich die Frage gestellt werden, ob die Dosis reduziert werden kann bzw. ob der Einsatz eines extrakorporalen Kreislaufunterstützungssystems erwogen werden sollte. Es gibt bisher keine Mortalitätsdaten, die den Nutzen des hämodynamischen Monitorings anhand von Zielkriterien belegen. Der Vorteil ergibt sich aber aus dem sparsameren Einsatz von Inotropika und Vasopressoren durch gewisse Zielkriterien.
Literatur
1.
Zurück zum Zitat Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153:586–600PubMed Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153:586–600PubMed
2.
Zurück zum Zitat Allwood MJ, Cobbold AF, Ginsburg J (1963) Peripheral vascular effects of noradrenaline, isopropylnoradrenaline and dopamine. Br Med Bull 19:132–136PubMed Allwood MJ, Cobbold AF, Ginsburg J (1963) Peripheral vascular effects of noradrenaline, isopropylnoradrenaline and dopamine. Br Med Bull 19:132–136PubMed
3.
Zurück zum Zitat No authors listed Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999;27:639–60 No authors listed Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999;27:639–60
4.
Zurück zum Zitat Calvin JE, Driedger AA, Sibbald WJ (1981) Does the pulmonary capillary wedge pressure predict left ventricular preload in critically ill patients? Crit Care Med 9:437–443CrossRefPubMed Calvin JE, Driedger AA, Sibbald WJ (1981) Does the pulmonary capillary wedge pressure predict left ventricular preload in critically ill patients? Crit Care Med 9:437–443CrossRefPubMed
5.
Zurück zum Zitat Packman MI, Rackow EC (1983) Optimum left heart filling pressure during fluid resuscitation of patients with hypovolemic and septic shock. Crit Care Med 11:165–169CrossRefPubMed Packman MI, Rackow EC (1983) Optimum left heart filling pressure during fluid resuscitation of patients with hypovolemic and septic shock. Crit Care Med 11:165–169CrossRefPubMed
6.
Zurück zum Zitat De Luca L, Colucci WS, Nieminen MS et al (2006) Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27:1908–1920CrossRefPubMed De Luca L, Colucci WS, Nieminen MS et al (2006) Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27:1908–1920CrossRefPubMed
7.
Zurück zum Zitat Innes CA, Wagstaff AJ (2003) Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs 63:2651–2671CrossRefPubMed Innes CA, Wagstaff AJ (2003) Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs 63:2651–2671CrossRefPubMed
8.
Zurück zum Zitat Russ MA, Prondzinsky R, Christoph A et al (2007) Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 35:2732–2739CrossRefPubMed Russ MA, Prondzinsky R, Christoph A et al (2007) Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 35:2732–2739CrossRefPubMed
9.
Zurück zum Zitat Russ MA, Prondzinsky R, Carter JM et al (2009) Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Crit Care Med 37:3017–3023CrossRefPubMed Russ MA, Prondzinsky R, Carter JM et al (2009) Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Crit Care Med 37:3017–3023CrossRefPubMed
10.
Zurück zum Zitat Rokyta R Jr, Pechman V (2006) The effects of Levosimendan on global haemodynamics in patients with cardiogenic shock. Neuro Endocrinol Lett 27:121–127PubMed Rokyta R Jr, Pechman V (2006) The effects of Levosimendan on global haemodynamics in patients with cardiogenic shock. Neuro Endocrinol Lett 27:121–127PubMed
11.
Zurück zum Zitat Delle Karth G, Buberl A, Geppert A et al (2003) Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 47:1251–1256CrossRefPubMed Delle Karth G, Buberl A, Geppert A et al (2003) Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 47:1251–1256CrossRefPubMed
12.
Zurück zum Zitat Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ et al (2006) Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 8:723–728CrossRefPubMed Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ et al (2006) Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 8:723–728CrossRefPubMed
13.
Zurück zum Zitat Christoph A, Prondzinsky R, Russ M et al (2008) Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction. Acute Card Care 10:49–57CrossRefPubMed Christoph A, Prondzinsky R, Russ M et al (2008) Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction. Acute Card Care 10:49–57CrossRefPubMed
14.
Zurück zum Zitat Fuhrmann JT, Schmeisser A, Schulze MR et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2008;36:2257–66; Editorial: 2450–2451: Comments: 2009;37(3):1181–1182; Erratum: 2008;36(10):2966 Fuhrmann JT, Schmeisser A, Schulze MR et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2008;36:2257–66; Editorial: 2450–2451: Comments: 2009;37(3):1181–1182; Erratum: 2008;36(10):2966
15.
Zurück zum Zitat Dellinger RP, Levy MM, Rhodes A et al (2012) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2013(41):580–637 Dellinger RP, Levy MM, Rhodes A et al (2012) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2013(41):580–637
16.
Zurück zum Zitat De Backer D, Creteur J, Silva E, Vincent JL (2003) Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 31:1659–1667CrossRefPubMed De Backer D, Creteur J, Silva E, Vincent JL (2003) Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 31:1659–1667CrossRefPubMed
17.
Zurück zum Zitat Al-Hesayen A, Azevedo ER, Newton GE, Parker JD (2002) The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure. J Am Coll Cardiol 39:1269–1274CrossRefPubMed Al-Hesayen A, Azevedo ER, Newton GE, Parker JD (2002) The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure. J Am Coll Cardiol 39:1269–1274CrossRefPubMed
18.
Zurück zum Zitat Gattinoni L, Brazzi L, Pelosi P et al (1995) A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 333:1025–1032CrossRefPubMed Gattinoni L, Brazzi L, Pelosi P et al (1995) A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 333:1025–1032CrossRefPubMed
19.
Zurück zum Zitat Hayes MA, Timmins AC, Yau EH et al (1994) Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 330:1717–1722CrossRefPubMed Hayes MA, Timmins AC, Yau EH et al (1994) Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 330:1717–1722CrossRefPubMed
20.
Zurück zum Zitat De Backer D, Biston P, Devriendt J et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779–789CrossRefPubMed De Backer D, Biston P, Devriendt J et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779–789CrossRefPubMed
21.
Zurück zum Zitat Mutlu GM, Factor P (2004) Role of vasopressin in the management of septic shock. Intensive Care Med 30:1276–1291PubMed Mutlu GM, Factor P (2004) Role of vasopressin in the management of septic shock. Intensive Care Med 30:1276–1291PubMed
22.
Zurück zum Zitat Sharshar T, Blanchard A, Paillard M et al (2003) Circulating vasopressin levels in septic shock. Crit Care Med 31:1752–1758CrossRefPubMed Sharshar T, Blanchard A, Paillard M et al (2003) Circulating vasopressin levels in septic shock. Crit Care Med 31:1752–1758CrossRefPubMed
23.
Zurück zum Zitat Tsuneyoshi I, Yamada H, Kakihana Y et al (2001) Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29:487–493CrossRefPubMed Tsuneyoshi I, Yamada H, Kakihana Y et al (2001) Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29:487–493CrossRefPubMed
24.
Zurück zum Zitat Varma A, Shah KB, Hess ML (2012) Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation. Congest Heart Fail. Jul 18(4):229–233 Varma A, Shah KB, Hess ML (2012) Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation. Congest Heart Fail. Jul 18(4):229–233
25.
Zurück zum Zitat Petros A, Lamb G, Leone A et al (1994) Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28:349CrossRef Petros A, Lamb G, Leone A et al (1994) Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28:349CrossRef
26.
Zurück zum Zitat Cotter G, Kaluski E, Blatt A et al (2000) L‑NMMA (a Nitric Oxide Synthase Inhibitor) is Effective in the Treatment of Cardiogenic Shock. Circulation 101:1358–1361CrossRefPubMed Cotter G, Kaluski E, Blatt A et al (2000) L‑NMMA (a Nitric Oxide Synthase Inhibitor) is Effective in the Treatment of Cardiogenic Shock. Circulation 101:1358–1361CrossRefPubMed
27.
Zurück zum Zitat Alexander JH, Reynolds HR, Stebbins AL et al (2007) Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 297(15):1657–1666CrossRefPubMed Alexander JH, Reynolds HR, Stebbins AL et al (2007) Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 297(15):1657–1666CrossRefPubMed
28.
Zurück zum Zitat De Backer D, Aldecoa C, Njimi H, Vincent JL (2012) Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. Crit Care Med 40:725–730CrossRefPubMed De Backer D, Aldecoa C, Njimi H, Vincent JL (2012) Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. Crit Care Med 40:725–730CrossRefPubMed
29.
30.
Zurück zum Zitat Peters JI, Utset OM (1989) Vasopressors in shock management: Choosing and using wisely. J Crit Illness 4:62 Peters JI, Utset OM (1989) Vasopressors in shock management: Choosing and using wisely. J Crit Illness 4:62
31.
Zurück zum Zitat Fincke R, Hochman JS, Lowe AM et al (2004) Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 44(2):340–348CrossRefPubMed Fincke R, Hochman JS, Lowe AM et al (2004) Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 44(2):340–348CrossRefPubMed
32.
Zurück zum Zitat Cotter G, Williams SG, Vered Z, Tan LB (2003) Role of cardiac power in heart failure. Curr Opin Cardiol 18(3):215–222 (May)CrossRefPubMed Cotter G, Williams SG, Vered Z, Tan LB (2003) Role of cardiac power in heart failure. Curr Opin Cardiol 18(3):215–222 (May)CrossRefPubMed
Metadaten
Titel
Einsatz von Vasopressoren und Inotropika im kardiogenen Schock
verfasst von
H. Lemm
S. Dietz
M. Janusch
Prof. Dr. med. M. Buerke
Publikationsdatum
18.01.2017
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 1/2017
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-016-4525-2

Weitere Artikel der Ausgabe 1/2017

Herz 1/2017 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.